

TABLE OF CONTENTS

Volume I

How to Use This Service

Table of Contents, Current Contents

Newsletters

Tab 100: Overview: Advertising and Promotion Regulation

Executive Summary ¶100
FDA’s Authority Over Advertising and Promotion ..¶110
 Federal Food, Drug and Cosmetic Act (FD&C Act) and Amendments..... ¶111
 Public Health Service Act (PHS Act)..... ¶112
 FDA’s Regulation Under the FD&C Act and the PHS Act..... ¶113
 Patient Protection and Affordable Care Act ¶114
External Influences on FDA Activity..... ¶120
 U.S. Congress..... ¶121
 Competitors’ Complaints..... ¶122
 Office of Inspector General..... ¶123
 Consumer and Industry Advocacy ¶124
 States ¶125
FTC’s Authority Over Advertising of FDA-regulated Products..... ¶130
Applicable Definitions..... ¶140
Guidelines of Professional Organizations..... ¶150
 ACCME Standards..... ¶151
 ACP-ASIM Guidelines ¶152
 AMA Guidelines ¶153
 AAMC Guidelines..... ¶154
Continuing Medical Education Policy ¶160
 Historical Context ¶161
 Final Guidance Provisions ¶162
First Amendment Issues and Cases ¶170

Tab 200: FDA’s Advertising Organization: Who Does What

Executive Summary ¶200
Office of the Commissioner ¶210
Center for Drug Evaluation and Research (CDER)... ¶220
Center for Biologics Evaluation and Research (CBER) ¶230
Center for Devices and Radiological Health (CDRH) . ¶240
Center for Food Safety and Applied Nutrition (CFSAN) ¶250
Center for Veterinary Medicine (CVM)..... ¶260
Center for Tobacco Products (CTP)..... ¶270

Tab 300: Federal Trade Commission

Executive Summary ¶300
 General Policies of FTC ¶301
 FTC Regulation of PBMs..... ¶302
Definitions of Labeling and Advertising ¶310
FTC’s Organizational Structure for Regulating Advertising and Promotion..... ¶320
Relationship Between FTC and FDA..... ¶330
 FTC-FDA Memorandum of Understanding ¶331
 Jurisdiction Over Prescription Drug Advertising ... ¶332
FTC’s Enforcement Activities..... ¶340
 Procedures for Reaching Decisions..... ¶341
 Consent Orders and Other Actions..... ¶342

Tab 400: Prescription Drugs

Executive Summary ¶400
 Summary of Requirements..... ¶401
 Definitions of Label, Labeling, Advertisements.. ¶402
General Policies for Promoting Prescription Drugs..... ¶410
Routine Submission of Promotional Materials to CDER..... ¶411
 Preclearance of Promotional Materials ¶412
 Fair Balance..... ¶413
 Use of Brief Summary..... ¶414
 Reminder and Other Advertisements Exempt from the Brief Summary Requirement ¶415
 Product Name and Placement ¶416
 Unapproved Legacy and Grandfathered Drugs..... ¶417
Specific Claims for Prescription Drugs..... ¶420
 Claims About Unapproved Products and New Uses for Approved Products ¶421
 Accelerated Approvals and Surrogate Markers... ¶422
 Off-label Claims ¶423
 Comparative and Superiority Claims ¶424
 Pharmacoeconomic and Quality-of-life Claims.. ¶425
 Price Advertising ¶426
 Other Claims for Prescription Drugs..... ¶427
Promotion to Health Care Professionals..... ¶430
 Educational and Scientific Events (Including CME)..... ¶431
 Single-sponsor Publications ¶432
 Drug Detailing by Company Representatives..... ¶433
 Drug Sampling ¶434
 Exhibits and International Meetings ¶435
 Responding to Requests for Information ¶436
 Promoting to Formularies and Managed Care Organizations ¶437

Tab 400 (cont'd)

Use of Celebrities	¶438
Disclosing Payments to Physicians	¶439
Direct-to-Consumer (DTC) Advertising	¶440
Evolution of DTC Policy	¶441
DTC Advertising in Print Media	¶442
DTC Advertising in Broadcast Media	¶443
AMA Guidelines on DTC Advertising	¶444
Press Materials and Financial Communications.....	¶450
Press Materials	¶451
Materials for the Financial Community	¶452
Advertising Policies for Specific Types of Products	¶460
Oral Contraceptives	¶461
Smoking Cessation Products	¶462
Cigarettes and Smokeless Tobacco	¶463
Aerosol Steroid Safety Information	¶464
Ionic and Nonionic Contrast Agents	¶465
Guidelines of Industry Organizations.....	¶470
PhRMA Code on Interactions with Health Care Professionals.....	¶471
PhRMA Guiding Principles of DTC Advertising	¶472
ABPI (U.K.) Code of Practice	¶473
Digital Health Coalition Guiding Principles for Social Media.....	¶474
Online Drug Promotion	¶480
Responding to Off-label Requests Online	¶481
Interactive and Real-time Promotions.....	¶482
Submitting Promotions for FDA Review	¶490
Draft Review Process	¶491
Formal Submission Process	¶492

Tab 500: Biologics

Executive Summary	¶500
Historical Differences Between Policies for Drugs and Biologics.....	¶501
General Policies for Advertising and Promoting Biologics.....	¶510
Review of Materials by CBER.....	¶511
Approval Criteria for Biologics Advertising and Promotion.....	¶512
Current Issues in Biologics Advertising and Promotion	¶520
CBER's Preclearance Policy	¶521
Comparative Advertising.....	¶522
Issuance of Press Releases and Other Materials to Financial Community	¶523
Educational and Scientific Events for Biologics.....	¶524
Online Biologics Promotion	¶525

Tab 600: Medical Devices

Executive Summary	¶600
Difference Between Policies for Drugs and Devices.....	¶601
Checklist for Device Promotion	¶602

CDRH's Policies for Monitoring Advertising and

Promotion of Devices.....	¶610
Routine Submission of Materials to CDRH	¶611
Preclearance of Promotional Materials	¶612
Competitors' Complaints.....	¶613
Current Issues in FDA's Policies for Medical Devices. ¶620	
Comparative Claims	¶621
Price Advertising/Pharmacoeconomics.....	¶622
Investigational Device Advertising	¶623
Promotion of Pending 510(k) Devices	¶624
Promoting Unapproved Uses of Marketed Devices	¶625
Direct-to-Consumer Promotion	¶626
FDA Policies for Specific Promotional Vehicles	¶630
Educational and Scientific Events	¶631
Public Relations Materials	¶632
Investor Relations Materials.....	¶633
Single-sponsor Publications	¶634
Device Detailing by Company Representatives	¶635
Exhibits.....	¶636
Online Device Promotion	¶637
Product Category Guidance.....	¶640
In Vitro Diagnostic (IVD) Products	¶641
Guidelines of Industry Organizations.....	¶650
AdvaMed's Code of Ethics on Interactions with Health Care Professionals.....	¶651
AdvaMed's Guiding Principles for DTC Device Advertising.....	¶652
HIA's Code of Principles.....	¶653

Tab 700: Foods, OTC Drugs, Nonrestricted Medical Devices and Cosmetics

Executive Summary	¶700
FTC-FDA MOU for Food Advertising and Labels	¶701
General Policies for Regulating Foods, OTC Drugs, Non-restricted Devices and Cosmetics	¶702
Regulations Under the FTC Act	¶703
Advertising Agency Responsibility.....	¶704
Food Advertising Regulation	¶710
Recent Cases and Activities	¶711
Nutrition Labeling and Education Act (NLEA)	¶712
Lanham Act Liability	¶713
Dietary Supplement Advertising Regulation.....	¶720
FTC Policy	¶721
FDA Policy	¶722
Dietary Supplement Enforcement Activity	¶723
OTC Drug Advertising Regulation by FTC	¶730
OTC Drug Advertising Policy.....	¶731
Analgesics Advertising Policy	¶732
Aspercreme Case Study	¶733
Diet Products and Programs	¶734
Industry's Code of Advertising Practices	¶735
'White Coat' Rule.....	¶736

Table of Contents

Tab 700 (cont'd)

Medical Device Advertising Regulation	¶740
Nonrestricted Device Case Studies	¶741
Restricted Device Case Studies.....	¶742
Cosmetics Advertising Regulation	¶750
Cross-classification of Cosmetics.....	¶751
FDA and FTC Enforcement Standards.....	¶752

Tab 800: Veterinary Medicine

Executive Summary	¶800
General Policies for Advertising and Promoting Veterinary Medicines	¶810
Educational and Scientific Events for Veterinary Medicines	¶811
History of ISSEA (Including CME).....	¶812
Case Study of Advertising and Promoting Veterinary Medicines	¶820
BST Case Study.....	¶821

Tab 900: FDA Enforcement

Executive Summary	¶900
The Basis for Increased FDA Enforcement.....	¶901
Responding to an Enforcement Action.....	¶902
FDA's Enforcement Tools	¶910
Notices of Violation (NOVs).....	¶911
Warning Letters	¶912
Seizures and Injunctions.....	¶913
Criminal Prosecution.....	¶914
Remedies for Advertising and Promotion Violations	¶920
'Dear Health Care Provider' Letters	¶921
Corrective Advertising	¶922
Instructions to Sales Representatives	¶923
Enforcement of Prescription Drug Advertising and Promotion	¶930
Untitled Letters for Prescription Drugs	¶931
Warning Letters for Prescription Drugs	¶932
Other Letters for Prescription Drugs	¶933
Enforcement of Biologics Advertising and Promotion	¶940
Warning Letters for Biologics	¶941
Enforcement of Medical Device Advertising and Promotion	¶950
Warning Letters and Safety Communications for Medical Devices	¶951
Enforcement Involving Judicial Action	¶960
Consent Agreements.....	¶961
Consent Decrees.....	¶962
Corporate Integrity Agreements	¶963
Alternative Dispute Resolution	¶970
The National Advertising Division	¶971
Health Claims Case Studies	¶972
Cooperative Enforcement Activity	¶980
State Prosecution	¶990

Appendix I: Federal Statutes and Regulations

For a detailed table of contents, see page 1 of specific appendix.

Appendix II: FDA, OIG and FTC Guidance

For a detailed table of contents, see page 1 of specific appendix for a list structured by topic, and page 7 for a list structured by type.

Prescription Drugs (Section A)
Biologics (Section B)
Medical Devices (Section C)
Veterinary Medicine (Section D)
General Material (Section E)
Food (Section F)

Volume II

Appendix III: Industry Standards

For a detailed table of contents, see page 1 of specific appendix.

Trade Associations
Medical Groups
Public Policy Organizations
Related Materials

Appendix IV: FDA Warning Letters

Recent Warning Letters to Drug Companies	3
Recent Warning Letters to Biologics Companies	21
Recent Warning Letters to Device Companies and Distributors	31
Recent Warning Letters for Veterinary Medicines	41
Recent Untitled Letters to Drug Companies	51
Recent Untitled Letters to Biologics Companies	121
Recent Advisory Action Letters to Veterinary Medicine Companies	131
Prescription Drugs (Section A)	
Biologics (Section B)	
Medical Devices (Section C)	
Veterinary Medicine (Section D)	
Citizen's Petition (Section E)	

Appendix V: Consent Orders

For a detailed table of contents, see page 1 of appendix.

Appendix VI: FTC Releases and FYIs

For a detailed table of contents, see page 1 of appendix.

Index

[The next page is Current Contents, Page 19.]